Clinical Trial Update: Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is investigating the combination of celecoxib, durvalumab, and tremelimumab for advanced or metastatic hepatocellular carcinoma, curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Celecoxib (Celecoxib)
• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Emory University | Conditions: Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma | Phase 2 | Status: RECRUITING